Ord Minnett Remains a Sell on Westpac Banking (WEBNF)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In addition to Ord Minnett, Westpac Banking also received a Sell from Morgans's Nathan Lead in a report issued today. However, yesterday, UBS maintained a Buy rating on Westpac Banking (Other OTC: WEBNF).
The company has a one-year high of $23.28 and a one-year low of $16.30. Currently, Westpac Banking has an average volume of 3,277.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WEBNF in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Insider
7 hours ago
- Business Insider
Ord Minnett Remains a Sell on Westpac Banking (WEBNF)
In a report released today, from Ord Minnett maintained a Sell rating on Westpac Banking, with a price target of A$30.00. The company's shares closed yesterday at $23.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Ord Minnett, Westpac Banking also received a Sell from Morgans's Nathan Lead in a report issued today. However, yesterday, UBS maintained a Buy rating on Westpac Banking (Other OTC: WEBNF). The company has a one-year high of $23.28 and a one-year low of $16.30. Currently, Westpac Banking has an average volume of 3,277. Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WEBNF in relation to earlier this year.
Business Insider
7 hours ago
- Business Insider
Morgan Stanley Reaffirms Their Buy Rating on Telstra Corporation Limited (TTRAF)
In a report released today, Andrew McLeod from Morgan Stanley maintained a Buy rating on Telstra Corporation Limited, with a price target of A$4.95. The company's shares closed last Friday at $3.35. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, McLeod is a 3-star analyst with an average return of 3.3% and a 55.56% success rate. McLeod covers the Communication Services sector, focusing on stocks such as Telstra Corporation Limited, CAR Group, and Event Hospitality & Entertainment Ltd.. In addition to Morgan Stanley, Telstra Corporation Limited also received a Buy from Jefferies's Roger Samuel in a report issued on August 1. However, today, Bell Potter maintained a Hold rating on Telstra Corporation Limited (Other OTC: TTRAF). Based on Telstra Corporation Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $11.6 billion and a net profit of $1.03 billion. In comparison, last year the company earned a revenue of $11.43 billion and had a net profit of $964 million
